What is CJC-1295 No DAC?
A short-acting GHRH-analogue research peptide studied in growth-hormone signaling and endocrine physiology. Naming conventions around CJC variants can be inconsistent, so identity should be verified on the COA.
What researchers study
- GHRH receptor signaling
- Growth-hormone release physiology
- Endocrine pathway research
- Metabolic and recovery models
Administration, dosing & shelf-life context
This commercial vial is presented as research use only. No human injection or dosing protocol is provided.
No established male human dose is provided for this research product.
No established female human dose is provided for this research product.
No validated shelf-life duration is stated on the live product page. Use lot-specific label, expiry/BUD and COA data.
Follow the seller label and COA. The seller recommends refrigeration of unopened peptide vials and protection from heat/light.
Research comparison ideas
These are literature/comparator ideas, not a recommendation to combine or co-administer compounds.
- Ipamorelin for comparative GH-axis research
- CJC-1295 / Ipamorelin blend as a pre-combined commercial reference
Evidence boundary
CJC nomenclature is often blurred commercially. Research interpretation should confirm the exact molecular identity, DAC status and analytical documentation for the lot.
Research-use boundary: This educational profile does not diagnose, treat, prescribe, calculate doses, or provide a self-experimentation protocol.